Revolutionizing Pancreatic Cancer Treatment: AIM Immunotech’s Ampligen Phase 2 Study Now Recruiting Patients!
Ongoing Efforts to Open Additional Clinical Sites for Recruitment at Premier Cancer Centers Across the U.S. and Europe Facilitating Patient Enrollment and Dosing for Pancreatic Cancer Treatment Study OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) AIM ImmunoTech Inc. has recently announced the launch of a Phase 2 study…